Status:
COMPLETED
Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study
Lead Sponsor:
Sandra Walker
Conditions:
Burns
Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Effective antimicrobial use in the burn population is important since this population is at an increased risk for infections during their stay in hospital as a result of their burn injury. Tobramycin ...
Eligibility Criteria
Inclusion
- Adult burn patient (≥ 18 years old)
- Total burn surface area less than 20%
- At least 48 hours after the time of the initial burn injury event
- Has a suspected or confirmed infection
- Has been receiving antibiotic therapy for at least 24 hours
Exclusion
- Pediatric patients (\< 18 years old);
- Pregnant
- Documented history of cochlear or vestibular injury
- Creatinine clearance \< 50 ml/min
- Requiring any modality of dialysis
- Has been receiving antibiotic therapy for longer than 72 hours
- Known allergy or adverse reaction to aminoglycoside antibiotics
- Known allergy or adverse reaction to sulfites
- Diagnosis of Parkinson's disease or myasthenia gravis
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02269969
Start Date
March 1 2015
End Date
December 1 2015
Last Update
December 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5